Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis
Condition: Atopic Dermatitis Interventions: Drug: Placebo; Drug: AK120 Sponsor: Akesobio Australia Pty Ltd Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials